PE20091969A1 - ANTICUERPOS ANTI-PirB - Google Patents
ANTICUERPOS ANTI-PirBInfo
- Publication number
- PE20091969A1 PE20091969A1 PE2009000673A PE2009000673A PE20091969A1 PE 20091969 A1 PE20091969 A1 PE 20091969A1 PE 2009000673 A PE2009000673 A PE 2009000673A PE 2009000673 A PE2009000673 A PE 2009000673A PE 20091969 A1 PE20091969 A1 PE 20091969A1
- Authority
- PE
- Peru
- Prior art keywords
- heavy chain
- seq
- pirb
- antibody
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
REFERIDA A UN ANTICUERPO ANTI-PirB AISLADO QUE SE UNE A UN EPITOPE PirB HUMANO SELECCIONADO DEL GRUPO QUE CONSISTE EN YW259.2, YW259.9 YW259.12. EL ANTICUERPO AISLADO COMPRENDE AL MENOS 1-3 SECUENCIAS DE LA REGION HIPERVARIABLE DE UNA CADENA PESADA SELECCIONADA DEL GRUPO QUE CONSISTE: CADENA PESADA DE YW259.2 (SEQ ID N0:4), CADENA PESADA DE YW259.9 (SEQ ID N0:5) Y CADENA PESADA DE YW259.12 (SEQ ID N0:6). DICHO ANTICUERPO IMPIDE LA INHIBICION DEL CRECIMIENTO NEURITICO POR NOGO66 Y MIELINA UTIL EN EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5294908P | 2008-05-13 | 2008-05-13 | |
US12/208,883 US20100047232A1 (en) | 2006-11-14 | 2008-09-11 | Modulators of neuronal regeneration |
US12/316,130 US20090232794A1 (en) | 2007-12-11 | 2008-12-09 | Modulators of neuronal regeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091969A1 true PE20091969A1 (es) | 2010-01-15 |
Family
ID=41319035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2009000673A PE20091969A1 (es) | 2008-05-13 | 2009-05-13 | ANTICUERPOS ANTI-PirB |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP2291405A1 (es) |
JP (1) | JP2011523359A (es) |
KR (1) | KR20110011676A (es) |
CN (1) | CN102089327A (es) |
AR (1) | AR071777A1 (es) |
AU (1) | AU2009246443A1 (es) |
BR (1) | BRPI0912769A2 (es) |
CA (1) | CA2723430A1 (es) |
IL (1) | IL209129A0 (es) |
MX (1) | MX2010012299A (es) |
PE (1) | PE20091969A1 (es) |
RU (1) | RU2010150754A (es) |
TW (1) | TW200950808A (es) |
WO (1) | WO2009140361A1 (es) |
ZA (1) | ZA201007976B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2787783A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
WO2011091181A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
JP6162219B2 (ja) * | 2012-04-17 | 2017-07-12 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列 |
CN103130898B (zh) * | 2013-01-28 | 2014-03-26 | 中国人民解放军第四军医大学 | Tat-lbd-pep融合蛋白及其在治疗中枢神经系统损伤疾病中的应用 |
EP3728318A2 (en) | 2017-12-22 | 2020-10-28 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
MX2021000009A (es) | 2018-07-09 | 2021-03-09 | Five Prime Therapeutics Inc | Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4). |
CN109439661B (zh) * | 2018-10-22 | 2020-10-23 | 西安医学院 | 抑制pirB表达的短发卡shRNA、慢病毒及其应用 |
WO2021222544A1 (en) | 2020-05-01 | 2021-11-04 | Ngm Biopharmaceuticals, Inc. | Ilt-binding agents and methods of use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1453540A4 (en) * | 2001-11-14 | 2005-06-01 | Immunex Corp | MODULATION OF THE LIR FUNCTION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
EP1981522B1 (en) * | 2006-01-23 | 2012-09-12 | President and Fellows of Harvard College | Compositions and methods for enhancing neuronal plasticity and regeneration |
-
2009
- 2009-05-13 AR ARP090101723A patent/AR071777A1/es not_active Application Discontinuation
- 2009-05-13 BR BRPI0912769A patent/BRPI0912769A2/pt not_active IP Right Cessation
- 2009-05-13 KR KR1020107027786A patent/KR20110011676A/ko not_active Application Discontinuation
- 2009-05-13 TW TW098115945A patent/TW200950808A/zh unknown
- 2009-05-13 PE PE2009000673A patent/PE20091969A1/es not_active Application Discontinuation
- 2009-05-13 RU RU2010150754/10A patent/RU2010150754A/ru not_active Application Discontinuation
- 2009-05-13 EP EP09747445A patent/EP2291405A1/en not_active Withdrawn
- 2009-05-13 CA CA2723430A patent/CA2723430A1/en not_active Abandoned
- 2009-05-13 MX MX2010012299A patent/MX2010012299A/es active IP Right Grant
- 2009-05-13 AU AU2009246443A patent/AU2009246443A1/en not_active Abandoned
- 2009-05-13 WO PCT/US2009/043757 patent/WO2009140361A1/en active Application Filing
- 2009-05-13 CN CN2009801265242A patent/CN102089327A/zh active Pending
- 2009-05-13 JP JP2011509642A patent/JP2011523359A/ja active Pending
-
2010
- 2010-11-04 IL IL209129A patent/IL209129A0/en unknown
- 2010-11-08 ZA ZA2010/07976A patent/ZA201007976B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009140361A1 (en) | 2009-11-19 |
ZA201007976B (en) | 2012-02-29 |
EP2291405A1 (en) | 2011-03-09 |
RU2010150754A (ru) | 2012-06-20 |
KR20110011676A (ko) | 2011-02-08 |
BRPI0912769A2 (pt) | 2015-10-13 |
CA2723430A1 (en) | 2009-11-19 |
CN102089327A (zh) | 2011-06-08 |
JP2011523359A (ja) | 2011-08-11 |
MX2010012299A (es) | 2010-12-06 |
AR071777A1 (es) | 2010-07-14 |
IL209129A0 (en) | 2011-01-31 |
TW200950808A (en) | 2009-12-16 |
AU2009246443A1 (en) | 2009-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20091969A1 (es) | ANTICUERPOS ANTI-PirB | |
AR122771A2 (es) | Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped | |
PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
PE20210115A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
AR124676A2 (es) | Formulación farmacéutica que comprende una droga biofarmacéutica | |
AR077016A1 (es) | Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales | |
PE20150222A1 (es) | Anticuerpos multiespecificos | |
PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
PE20110382A1 (es) | Tratamiento de enfermedad autoinmunitaria e inflamatoria | |
ES2685823T3 (es) | Anticuerpos antagonistas anti-CD40 | |
CY1116488T1 (el) | Αντισωματα anti-προπερδινης | |
ES2667568T3 (es) | Anticuerpo anti-B7-H3 | |
AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
UY33407A (es) | Anticuerpos específicos del factor gdf8 humano | |
PE20120429A1 (es) | Proteinas de enlace de miostatina | |
PE20080035A1 (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina | |
PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
PE20141271A1 (es) | Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2 | |
AR075604A1 (es) | Anticuerpos contra un ligando que induce proliferacion (april) | |
RS54468B1 (en) | MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT | |
AR091702A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
PE20110797A1 (es) | Anticuerpos anti mn |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |